• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PPD names Hill CEO

PPD names Hill CEO

September 20, 2011
CenterWatch Staff

CRO PPD, which has been the subject of takeover speculation since July, has named Raymond Hill its new chief executive officer, filling a position that was vacant since mid-May, according to a PharmaTimes report.

Hill comes to PPD from IMS Health, where he spent eight years and was most recently president of IMS Consulting Group. Hill oversaw a strategy of “aggressive organic and acquisition-based growth,” said PPD, helping to push up annual revenues five-fold over seven years and transform IMS from its data and market-research roots into a leader in pharmaceutical consulting.

PPD’s previous CEO, David Grange, retired May 18 after holding the post since mid-2009. Since then, Fred Eshelman has been filling in at the helm as executive chairman.

In July, PPD launched a review of its strategic planning and capital structure to see whether more value could be unlocked for shareholders. Eshelman insisted at the time that the company was “not engaged in any discussions around a combination with other clinical research providers.”

However, that did not rule out private equity interests, and in mid-August reports circulated that Carlyle Group was in talks, with the possibility of enlisting other private equity firms in a bid for PPD.  Speculation about Carlyle and PPD has cooled somewhat in recent weeks, though.

Before joining IMS Health, Hill was senior vice president for Acumen Sciences. He previously held a number of positions during an eight-year stint at A T Kearney, including global head of the pharmaceuticals and health care practice.

“With more than 20 years of experience in the life sciences arena, Ray brings keen strategic acumen as a proven leader who has grown global client services businesses in the pharmaceutical industry,” Eshelman said.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing